Tonix Pharmaceuticals Holding Corp.
https://www.tonixpharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Tonix Pharmaceuticals Holding Corp.
Breaking The Pain Market’s Addiction To Opioids
The recent success of Vertex in acute pain merely highlights the agonizingly slow process elsewhere, particularly in chronic pain indications.
Finance Watch: Syndax Has A Standout Post-ASH Offering As Peers Scramble For Cash
Public Company Edition: Syndax grossed $230m in a follow-on public offering based on positive results for its menin inhibitor in leukemia, but the FOPO was an outlier relative to other companies, which relied on private placements, debt and other options to raise cash in a tough market.
Tonix Shutters MDD Candidate After Phase II Miss
Tonix’s once-daily formulation of tianeptine, widely used to treat depression in Europe, failed to improve depression severity in a Phase II study and will be discontinued, the latest R&D setback for the biotech.
Bionomics Posts Positive Data In PTSD With Struggling Anxiety Drug
After failing in a Phase II trial in social anxiety disorder, Bionomics thinks mid-stage data for BNC210 in post-traumatic stress disorder may now position the drug as a novel therapy for PTSD.
Company Information
- Industry
-
Pharmaceuticals
- Drug Delivery
- Vaccines
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Other Names / Subsidiaries
-
- Krele Pharmaceuticals
- Tonix Pharmaceuticals Holding Corporation
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice